---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-23-000079"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:23:06.220554+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics annual meeting results: directors elected, auditor ratified

## Summary
- Electors voted to re-elect three Class III directors: Jennifer Cook, David Schenkein, and Ryan J. Watts.
- Ernst & Young LLP ratified as independent auditor for FY 2023 with 112,694,203 votes for.
- Advisory vote on executive compensation approved with 98,002,580 votes for.
- 82.58% of outstanding shares (112,922,471) were represented at the meeting.

## SEC filing metadata
- accession: 0001714899-23-000079
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000079/0001714899-23-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000079/dnli-20230601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-23-000079
- JSON: https://secwatch.observer/filing/0001714899-23-000079.json
- Plain text: https://secwatch.observer/filing/0001714899-23-000079.txt

## Key facts
- Shareholder Votes
  Denali Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 112,694,203 198,540 29,728 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000079/0001714899-23-000079-index.htm
- Shareholder Votes
  Denali Therapeutics Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2023-06-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal 3 - Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 98,002,580 6,571,884 50,220 8,297,787
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000079/0001714899-23-000079-index.htm
- Shareholder Votes
  Denali Therapeutics Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders. at the 2023-06-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal 1 - Election of Directors Election of three Class III directors to hold office until the 2026 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal. Nominees For Withheld Broker Non-Votes Jennifer Cook 87,451,911 17,172,773 8,297,787 David Schenkein, M.D. 87,642,096 16,982,588 8,297,787 Ryan J. Watts, Ph.D. 103,702,078 922,606 8,297,787
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000079/0001714899-23-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.